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Abstract. Although gastric cancer is increasingly being 
detected at an early stage of development, diffuse growth-type 
malignant tumors, such as scirrhous gastric cancer, are usually 
at an advanced stage at the time of diagnosis, resulting in poor 
treatment outcomes. The aim of this study was to determine 
whether the K-sam gene and keratinocyte growth factor (KGF) 
expression may be used to identify malignant tumors with a 
poor prognosis. K-sam and KGF expression was retrospec-
tively evaluated in samples from 86 patients with early and 
advanced gastric cancer according to type, by examining 
serum levels and using immunohistochemical staining. The 
associations with clinicopathological characteristics and 
survival were also examined. The mean serum KGF levels were 
11.191±3.808 pg/ml in early stage and 10.715±3.4991 pg/ml 
in advanced gastric cancer patients. KGF levels were signifi-
cantly higher in types 4 and 5 (14.498±3.812 pg/ml, n=6) 
compared with types 1, 2 and 3 (10.747±3.571 pg/ml, n=80; 
P=0.028). Stage classification was identified as the only 
significant factor which determined overall survival. Patients 
with KGF-positive tumors had significantly higher serum KGF 
levels compared with those who had KGF-negative tumors. 
Patients with K-sam-positive tumors had significantly higher 
KGF levels compared with those who had K-sam-negative 
tumors. Pathological KGF expression was not significantly 
correlated with the degree of differentiation; however, there 
was a positive correlation between high K-sam expression in 
scirrhous gastric tumors and serum KGF levels. The present 
study revealed that high serum KGF levels are a risk factor 
for diffuse infiltrative gastric cancer and may provide a simple 
method of identifying patients with a poor prognosis among 
previously diagnosed preoperative gastric cancer patients.
Introduction
Recent advances in diagnostic techniques have allowed gastric 
cancer to be detected early in an increasing number of cases 
and the treatment outcomes of gastric cancer as a whole have 
been significantly improved. However, diffuse growth-type 
malignant tumors, such as scirrhous gastric cancer, remain 
difficult to diagnose during the early stages of development 
and are usually at an advanced stage at the time of diagnosis, 
leading to poor treatment outcomes.
Cell motility is an important factor in primary tumor 
isolation and invasion; the cell adhesion factors that have been 
identified to promote cell motility include epidermal growth 
factor (EGF), transforming growth factor (TGF)-β and hepato-
cyte growth factor (HGF) (1-7). The present study investigated 
fibroblast growth factor (FGF), which is involved in fibroblast 
proliferation (8-11). With regard to the signal transmission 
pathways involved in scirrhous gastric cancer, scirrhous gastric 
cancer cells grow in the submucosa (SM), which is dense with 
lymph nodes, rather than on the mucosal surface where they 
would be exposed to gastric acid (12). FGF7 is produced by 
fibroblasts inside the stomach and promotes proliferation 
of scirrhous gastric cancer cells via FGFR2 receptors; the 
production of HGF and TGF-β promotes infiltration in a 
similar manner. Since TGF-β also promotes the proliferation 
of fibroblasts, these factors have the potential to induce the 
rapid infiltration and proliferation of scirrhous gastric cancer 
cells (13-15).
The K-sam gene, which is known to exacerbate scirrhous 
gastric cancer, has also been revealed to be homologous to 
other genes, including FGFR2, KGFR and Bek. An evaluation 
of the association of K-sam with keratinocyte growth factor 
(KGF) expression may enable the identification of malignant 
tumors with a poor prognosis (16-20).
Materials and methods
Patients and sample collection. A total of 86 patients under-
went gastrectomy for carcinoma (early cancer, 49 cases; 
advanced cancer, 37 cases) between 1999 and 2003. The 
clinical characteristics of the patients are listed in Table I. 
A total of 31 patients who underwent surgery for a benign 
disease (e.g., inguinal hernia, gallbladder stone) and did not 
have cancer, as confirmed on prior screening, were enrolled as 
the control group in this study. Blood samples were obtained 
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preoperatively from the 86 gastric carcinoma and 31 control 
patients. These samples were centrifuged and then preserved 
at -80˚C in a freezer. The serum KGF concentration was 
estimated using a KGF ELISA kit and a clinical/oncological 
analysis was completed >5 years after the surgery.
A total of 86 patients who had undergone a primary 
tumor resection and were histologically diagnosed with 
sporadic gastric cancer were included in this study. None 
of the patients had received preoperative radiation therapy 
and/or chemotherapy. The samples were fixed in 10% formal-
dehyde solution and embedded in paraffin. The samples were 
sectioned (4-µm) and mounted on glass slides. Pathological 
diagnosis and classifications were determined according 
to the Japanese Classification of Gastric Carcinoma by the 
Japanese Gastric Cancer Association (21). Additionally, 
based on this classification, tumor invasion in the mucosa 
(M) and SM was determined as early-stage cancer, while 
tumor invasion in the muscularis propria (MP), subserosa 
(SS), serosa (SE), and adjacent structures (SI) was evalu-
ated as advanced-stage cancer, regardless of lymph node or 
distant metastases.
Antibodies and reagents. A rabbit polyclonal antibody against 
K-sam was purchased from Immuno-Biological Laboratories 
Co., Ltd. (9G-915, dilution 1:40; Gunma, Japan). A mouse 
monoclonal antibody against KGF was obtained from R&D 
Systems, Inc. (MAB2511, dilution 1:50; Minneapolis, MN, 
USA). Skim milk, Dako EnVision + System-HRP (DAB; 
catalog nos. K4006 and K4011), Target Retrieval Solution 
pH 9.0 and diaminobenzidine were purchased from Dako 
(Carpinteria, CA, USA).
Amplifying Wash Buffer™ 20X (catalog no. AA4; 
ProHisto, Columbia, SC, USA), xylene, ethanol, H2O2, 
coverslips (24x50 mm, no. 1 thickness; Chase Scientific 
Glass, Inc., Rockwood, TN, USA) and hematoxylin (Gill-1, 
catalog no. 23-245653; Thermo Fisher Scientific, Inc., 
Kanagawa, Japan) were also used in this study.
Serological investigation. The venous blood samples, which 
were obtained prior to surgery, were centrifuged and the puri-
fied serum was stored at -80˚C. The frozen serum was allowed 
to thaw naturally prior to examination. Serum KGF levels 
were measured using the ELISA method with a Quantikine 
Human KGF ELISA kit. A cuvette port internal microplate 
spectrophotometer was used, with a biquadratic approxima-
tion formula.
Subsequently, 100 µl assay diluent and 100 µl of sample 
were added to each well. The wells were covered with the 
adhesive strip provided and then incubated for 3 h at room 
temperature. Each well was aspirated and washed 4 times; for 
washing, each well was filled with wash buffer (400 µl).
KGF conjugate (200 µl) was added to each well. The wells 
were covered with a new adhesive strip and incubated for 
2 h at room temperature. Each well was then aspirated and 
washed 4 times, as previously described. Substrate solution 
(200 µl) was then added to each well, followed by incubation.
Immunohistochemical techniques. The immunohistochemical 
detection of K-sam and KGF was performed according to the 
manufacturer's instructions. Briefly, the slides were deparaf-
Table I. Patient characteristics.
Characteristics n (%)
Age, mean (SD) 63.33 (9.5)
Gender
  Male 66 (76.74)
  Female 20 (23.26)
Macroscopic types
  Type 0 53 (61.63)
  Type 1 4 (4.65)
  Type 2 15 (17.44)
  Type 3 8 (9.30)
  Type 4 5 (5.81)
  Type 5 1 (1.16)
Histological types
  Papillary 2 (2.33)
  Well-differentiated (tub1) 27 (31.40)
  Moderately differentiated (tub2) 16 (18.60)
  Poorly differentiated (por1) 20 (23.26)
  Poorly differentiated (por2) 12 (13.95)
  Signet-ring cell 6 (6.98)
  Mucinous 3 (3.49)
Depth of tumor invasion
  M 22 (25.58)
  SM 27 (31.40)
  MP 8 (9.30)
  SS 13 (15.12)
  SE 16 (18.61)
Lymphatic invasion
  ly0 37 (43.02)
  ly1 31 (36.05)
  ly2 14 (16.28)
  ly3 4 (4.65)
Venous invasion
  v0 69 (80.23)
  v1 16 (18.61)
  v2 1 (1.16)
Lymph node metastasis
  n0 63 (73.26)
  n1 14 (16.28)
  n2 6 (6.98)
  n3 1 (1.16)
  n4 2 (2.33)
Japanese clinical stage
  Ia 46 (53.49)
  Ib 14 (16.28)
  II 12 (13.95)
  IIIa 5 (5.81)
  IIIb 3 (3.49)
  IVa 2 (2.33)
  IVb 4 (4.65)
SD, standard deviation; M, mucosa; SM, submucosa; MP, muscularis 
propria; SS, subserosa; SE, serosa.
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finized in xylene and hydrated in decreasing concentrations 
of ethyl alcohol. The tissues were heated for 20 min at 105˚C 
by autoclave in Target Retrieval Solution pH 9.0. Then, the 
sections were deparaffinized and incubated with 3% hydrogen 
peroxide in methanol for 15 min to block the endogenous 
peroxidase activity. The sections were washed in phosphate-
buffered saline (PBS) and incubated in skim milk for 10 min 
to reduce the non-specific antibody binding.
The specimens were incubated with K-sam (2.5 mg/ml) 
or KGF antibody (2.5 mg/ml) overnight at 4˚C, followed by 
3 washes with PBS. The sections were incubated with labeled 
polymer-HRP (bottle 2) for 30 min at room temperature, 
followed by 3 washes with PBS. The slides were treated with 
ready-to-use AEC substrate-chromogen solution for 3 min and 
washed with PBS 3 times. Finally, the slides were incubated 
in PBS diaminobenzidine and 1% hydrogen peroxide v/v for 
60 or 90 sec, counterstained with Mayer's hematoxylin and 
mounted.
Identification of K-sam and KGF using immunohistochemical 
staining. Known cases of scirrhous gastric cancer were used 
as controls for KGF and K-sam expression. KGF was immu-
nologically localized mainly in the cytoplasm, while K-sam 
was in the cell membrane and cytoplasm (22). Hematoxylin 
and eosin (H&E) staining was also used on the control slides 
to select infiltrative regions. Infiltrative regions were defined 
as areas on the serosal side where cancer cells were initially 
observed. Microscopy revealed that cancer cells were continu-
ously present from the mucosa to the serosa.
K-sam antibodies were weakly stained in the gastric cancer 
mucosa. Tumors were evaluated as positive for K-sam when 
≥50% of tumor cells in the infiltrative region were stained 
more intensely than healthy epithelial cells in the same region 
(Fig. 1A and B). In the infiltrative region, tumors were evalu-
ated as positive for KGF when ≥2 fibroblasts in the interstitium 
were stained more intensely than the fundic gland at a magni-
fication of x200 (Fig. 1C and D).
Statistical analysis. The Chi-square and Mann-Whitney U 
tests were used to determine the significance of the differ-
ences between the covariates. The survival durations were 
calculated using the Kaplan-Meier method and analyzed using 
the log-rank test to compare the cumulative survival durations 
in the patient groups. Additionally, a Cox proportional hazards 
model was used to determine multivariate hazard ratios for 
the study parameters. In all the tests, P<0.05 was considered 
to indicate a statistically significant difference. The JMP 8.0.1 
software program (SAS Institute, Inc., Cary, NC, USA) was 
used for the analysis.
Results
Association of serological KGF levels with clinicopatho-
logical factors. Fig. 2 shows the association between clinical/
oncological factors and serum KGF levels. The average KGF 
level in early-stage gastric cancer was 11.191±3.808 pg/ml 
and in advanced gastric cancer was 10.715±3.4991 pg/ml; the 
difference between these results was small. Analysis of the 
macroscopic type revealed that KGF levels were significantly 
higher in types 4 and 5 (14.498±3.812 pg/ml, n=6) compared 
with types 1, 2 and 3 (10.747±3.571 pg/ml, n=80; P=0.028; 
Fig. 2). With regard to the serum KGF levels, there were no 
significant differences in histological type, invasion depth, 
lymph node infiltration, vascular infiltration, lymph node 
metastasis or stage classification (Table II). For the overall 
survival rate, stage classification was the only significant factor 
that determined prognosis (Table III). Tumors were classified 
as high- or low-KGF with a cut-off value of 14.608 pg/ml 
(the mean + 1xSD). The Kaplan-Meier method was used to 
calculate the survival rate curves, with the high-KGF group 
trending towards a poorer prognosis (Fig. 3).
Pathological KGF/K-sam expression. For the association 
between pathological KGF expression and histological type, 
there was a tendency for KGF-positive tumors to be poorly 
differentiated; however, this difference was not significant.
Exploring the association between pathological KGF 
expression and serum KGF levels revealed that the mean level 
for patients with KGF-negative tumors was 10.121±3.329 pg/ml, 
while it was 12.131±3.861 pg/ml for patients with KGF-positive 
tumors. Patients with KGF-positive tumors had significantly 
higher KGF levels compared with patients with KGF-negative 
tumors (Fig. 4).
As demonstrated in previous studies, the K-sam gene 
is highly expressed in scirrhous gastric cancer (22). The 
mean KGF level was 10.456±3.362 pg/ml in patients with 
K-sam-negative tumors and 13.099±4.212 pg/ml in patients 
with K-sam-positive tumors. Patients with K-sam-positive 
tumors had significantly higher KGF levels than those with 
K-sam-negative tumors (Fig. 5).
Pathological KGF expression was not significantly corre-
lated with the degree of differentiation, while there was a 
positive correlation between high K-sam expression and serum 
KGF levels in scirrhous gastric tumors.
Figure 1. Immunohistochemical determination of K-sam and KGF. 
KGF, keratinocyte growth factor. (A and B) Tumors were evaluated as positive 
for K-sam when ≥50% of tumor cells in the infiltrative region were stained 
more intensely than healthy epithelial cells in the same region. (C and D) 
In the infiltrative region, tumors were evaluated as positive for KGF when 
≥2 fibroblasts in the interstitium were stained more intensely than the fundic 
gland (magnification, x200).
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Patients with a high expression of the K-sam gene also 
tended to have high serum KGF levels. It is possible that serum 
KGF levels may be correlated with high K-sam expression and 
diffuse infiltrative gastric cancer.
Discussion
Various mechanisms have been hypothesized to exist in the 
interactions between cancer and interstitial cells. Interstitial 
cell growth and angiogenesis factors produced by cancer 
cells are considered to trigger interstitial cell recruitment 
and angiogenesis. It has also been shown that cells recruited 
by cancer cells produce various tumor growth factors which 
promote growth and give rise to the invasive capacity of 
cancer cells. In a number of these molecular mechanisms, 
the surrounding cells are hypothesized to have paracrine-like 
Figure 2. Association between serum KGF levels and the macroscopic type. 
KGF, keratinocyte growth factor. Figure 3. Overall survival using the Kaplan-Meier method in the groups classified as high- or low-KGF, with a cut-off value of 14.608 pg/ml (the 
mean + 1xSD). The high-KGF group exhibited a tendency towards a poorer 
prognosis. KGF, keratinocyte growth factor.
Table II. Univariate analysis of serum KGF.
Factors n Mean SD P-value
Histological types
  Papillary/well- to moderately differentiated 45 11.242 3.797 NS
  Poorly differentiated/signet-ring cell/mucinous 41 10.753 3.601
Depth of tumor invasion
  M/SM 49 11.191 3.808 NS
  MP/SS/SE 37 10.768 3.568
Lymphatic invasion
  ly0/ly1 68 10.949 3.72 NS
  ly2/ly3 18 11.235 3.68
Venous invasion
  v0 69 10.758 3.445 NS
  v1/v2 17 12.029 4.537
Lymph node metastasis
  No metastasis 64 11.253 3.594 NS
  Metastasis 22 10.3 3.963
Japanese clinical stage
  Ia/Ib/II 72 11.015 3.573 NS
  IIIa/IIIb/IVa/IVb 14 10.977 4.403
Macroscopic types
  Type 0/1/2/3 80 10.747 3.571 P=0.028
  Type 4/5   6 14.498 3.812
KGF, keratinocyte growth factor; SD, standard deviation; NS, not significant; M, mucosa; SM, submucosa; MP, muscularis propria; 
SS, subserosa; SE, serosa.
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functions, resulting from the molecules produced and released 
by cancer or interstitial cells (15).
The growth factors previously investigated, including KGF 
and K-samII, have been shown to mainly contribute to fibrosis. 
The molecules involved in this process have an impact on 
cancer cells, fibroblasts and inflammatory cells, creating the 
properties required for rapidly progressing, diffuse infiltrative 
gastric cancer cells (13).
In the present study, the mechanisms that control the 
development of diffuse infiltrative gastric cancer were exam-
ined through the serological and pathological evaluation 
of fibroblast growth factors and their receptors and coding 
genes. Serum KGF levels in patients with gastric cancer were 
demonstrated to be higher in those who had tumors with a 
poor prognosis and exhibited significant cell proliferation and 
infiltration. This suggests that the K-sam gene, which codes for 
Table III. Univariate and multivariate analysis of overall survival.
 Multivariate  Univariate
 ---------------------------------------------------- -------------------------------------------------------  
Factors Risk ratio 95% CI  Risk ratio 95% CI P-value
Depth of tumor invasion 1.159 0.033-35.213 16.778 3.337-304.762 NS
(M, SM) vs. (MP, SS, SE)
Infiltration 1.468 0.049-43.966 18.568 3.692-377.311 NS
(α, β) vs. (γ)
Vascular invasion 5.133 0.728-34.157 8.614 2.858-28.649 NS
(v0) vs. (v1, v2)
Lymphatic invasion 0.329 0.054-1.757 7.278 2.474-23.928 NS
(ly0, ly1) vs. (ly2, ly3)
Histological type 2.158 0.478-15.611 6.389 1.714-41.301 NS
(Papillary/well- to moderately differentiated) vs.
(poorly differentiated/signet-ring cell/mucinous)
Lymph node metastasis 0.532 0.040-6.389 0.053 0.008-0.197 NS
(No metastasis) vs. (metastasis)
Japanese clinical stage 28.004 2.770-937.265 48.436 12.788-315.979 0.00031
(Ia, Ib, II) vs. (IIIa, IIIb, IVa, IVb)
Macroscopic type 0.714 0.092-6.209 20.306 6.193-66.794 NS
(Type 0, 1, 2, 3) vs. (type 4, 5)
Serum KGF level 1.124 0.225-5.807 1.731 0.462-5.300 NS
(≥mean + 1xSD) vs. (<mean + 1xSD)
CI, confidence interval; M, mucosa; SM, submucosa; MP, muscularis propria; SS, subserosa; SE, serosa; NS, not significant; KGF, keratinocyte 
growth factor.
Figure 4. Association between serum KGF levels and the histological pres-
ence of KGF. KGF, keratinocyte growth factor.
Figure 5. Association between serum KGF levels and the histological presence 
of K-sam. KGF, keratinocyte growth factor.
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the pathological KGF receptor KGFR, was highly expressed. 
Therefore, it is possible that KGFR expression may also be 
high and that KGF is released into the serum, leading to the 
association between the high expression of the K-sam gene 
and serum KGF levels.
Serum KGF was significantly higher in patients with 
macroscopic types 4 and 5, regardless of the stage of cancer 
progression. This finding indicates that it may be possible to 
search serologically for malignant tumors with a poor prog-
nosis that exhibit significant proliferation and infiltration, such 
as scirrhous gastric cancer.
Previous studies have shown that the types of gastric cancer 
that have a high pathological expression of K-sam or KGF are 
malignant tumors with a poor prognosis that induce significant 
proliferation and infiltration, such as scirrhous gastric cancer. 
Therefore, this has been identified as one factor which may 
determine prognosis (23,24).
In the present study, there was a positive correlation 
between pathological KGF expression and the serum KGF 
levels, in addition to a positive correlation between patho-
logical K-sam expression and KGF levels, which indicates an 
association between serum KGF and diffuse malignant tumors. 
Since there was no correlation with cancer invasion depth or 
the stage of progression, it may be possible to identify gastric 
cancer patients who have the potential to develop malignant 
tumors with a poor prognosis that exhibit significant prolif-
eration and infiltration, such as scirrhous gastric cancer, at the 
precursor lesion stage. However, the investigation of survival 
rates conducted in this study did not identify serum KGF as a 
factor determining prognosis. Further studies are required to 
elucidate its clinical significance as a biomarker.
Currently, diffuse growth-type malignant tumors, such as 
scirrhous gastric cancer, remain difficult to diagnose during 
the early stages of development and are usually at an advanced 
stage at the time of diagnosis, which leads to poor treatment 
outcomes.
The results of the present study suggest that serum KGF 
is a risk factor for diffuse infiltrative gastric cancer and may 
provide a simple method of identifying patients with a poor 
prognosis among previously diagnosed preoperative gastric 
cancer patients.
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